ARS Pharmaceuticals, Inc. Other Comprehensive Income (Loss), Net of Tax
ARS Pharmaceuticals, Inc. (SPRY) reported Other Comprehensive Income (Loss), Net of Tax of $8.17 million for the 12-month period ending 2024-12-31, per its 10-K filed 2025-03-20.
Financial Statements › Income Statement › Unrealized Gains
us-gaap:OtherComprehensiveIncomeLossNetOfTax · last filed 2025-03-20
- ARS Pharmaceuticals, Inc. other comprehensive income (loss), net of tax for the quarter ending 2024-12-31 was $49.81M.
- ARS Pharmaceuticals, Inc. other comprehensive income (loss), net of tax for the quarter ending 2024-09-30 was -$18.64M.
- ARS Pharmaceuticals, Inc. other comprehensive income (loss), net of tax for the quarter ending 2024-06-30 was -$12.54M.
- ARS Pharmaceuticals, Inc. other comprehensive income (loss), net of tax for the quarter ending 2024-03-31 was -$10.46M.
- ARS Pharmaceuticals, Inc. other comprehensive income (loss), net of tax for fiscal 2024 was $8.17M.
- ARS Pharmaceuticals, Inc. other comprehensive income (loss), net of tax for fiscal 2023 was -$54.72M.
- ARS Pharmaceuticals, Inc. other comprehensive income (loss), net of tax for fiscal 2022 was -$34.27M.
- ARS Pharmaceuticals, Inc. other comprehensive income (loss), net of tax for fiscal 2021 was -$20.24M.
| Period end | Other Comprehensive Income (Loss), Net of Tax 3 month | Other Comprehensive Income (Loss), Net of Tax 3 month as first filed | Other Comprehensive Income (Loss), Net of Tax 6 month | Other Comprehensive Income (Loss), Net of Tax 9 month | Other Comprehensive Income (Loss), Net of Tax 12 month | Other Comprehensive Income (Loss), Net of Tax 12 month as first filed |
|---|---|---|---|---|---|---|
| 2024-12-31 | $49.81M derived: 10-K 12 month − 3 quarters · filed 2025-03-20 | $31.17M derived: sum of 2 quarters · filed 2025-03-20 | $18.63M derived: sum of 3 quarters · filed 2025-03-20 | $8.17M 10-K · filed 2025-03-20 | ||
| 2024-09-30 | -$18.64M 10-Q · filed 2024-11-13 | -$31.18M derived: sum of 2 quarters · filed 2024-11-13 | -$41.65M derived: sum of 3 quarters · filed 2024-11-13 | |||
| 2024-06-30 | -$12.54M 10-Q · filed 2024-11-13 | -$23.00M derived: sum of 2 quarters · filed 2024-11-13 | ||||
| 2024-03-31 | -$10.46M 10-Q · filed 2024-11-13 | |||||
| 2023-12-31 | -$54.72M 10-K · filed 2025-03-20 | |||||
| 2023-09-30 | -$14.85M 10-Q · filed 2024-11-13 | -$32.47M derived: sum of 2 quarters · filed 2024-11-13 | -$47.77M derived: sum of 3 quarters · filed 2024-11-13 | |||
| 2023-06-30 | -$17.62M 10-Q · filed 2024-11-13 | $17.62M 10-Q · filed 2023-08-10 | -$32.92M derived: sum of 2 quarters · filed 2024-11-13 | |||
| 2023-03-31 | -$15.30M 10-Q · filed 2024-11-13 | |||||
| 2022-12-31 | -$34.27M 10-K · filed 2024-03-21 | |||||
| 2022-09-30 | -$6.58M 10-Q · filed 2023-11-09 | -$13.00M derived: sum of 2 quarters · filed 2023-11-09 | -$20.25M derived: sum of 3 quarters · filed 2023-11-09 | |||
| 2022-06-30 | -$6.42M 10-Q · filed 2023-11-09 | -$300.00K 10-Q · filed 2022-08-11 | -$13.67M derived: sum of 2 quarters · filed 2023-11-09 | |||
| 2022-03-31 | -$7.25M 10-Q · filed 2023-11-09 | -$922.00K 10-Q · filed 2022-05-12 | ||||
| 2021-12-31 | -$20.24M 10-K · filed 2023-03-23 | -$89.80M 10-K · filed 2022-03-31 | ||||
| 2021-09-30 | -$22.69M 10-Q · filed 2021-11-10 | -$47.19M derived: sum of 2 quarters · filed 2021-11-10 | -$66.05M derived: sum of 3 quarters · filed 2021-11-10 | |||
| 2021-06-30 | -$24.50M 10-Q · filed 2021-11-10 | -$43.36M derived: sum of 2 quarters · filed 2021-11-10 | ||||
| 2021-03-31 | -$18.87M 10-Q · filed 2021-11-10 | |||||
| 2020-12-31 | -$32.95M 10-K · filed 2022-03-31 | |||||
| 2020-09-30 | -$8.12M 10-Q · filed 2021-11-10 | -$14.58M derived: sum of 2 quarters · filed 2021-11-10 | -$19.86M derived: sum of 3 quarters · filed 2021-11-10 | |||
| 2020-06-30 | -$6.47M 10-Q · filed 2021-11-10 | -$11.75M derived: sum of 2 quarters · filed 2021-11-10 | ||||
| 2020-03-31 | -$5.28M 10-Q · filed 2021-11-10 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Atea Pharmaceuticals, Inc. (AVIR) | United States | $0.414B | -2.26 |
| RELMADA THERAPEUTICS, INC. (RLMD) | United States | $0.406B | -11.92 |
| Opus Genetics, Inc. (IRD) | United States | $0.406B | -3.16 |
| DiaMedica Therapeutics Inc. (DMAC) | United States | $0.423B | -10.11 |
| Arcturus Therapeutics Holdings Inc. (ARCT) | $0.402B | -2.05 | |
| GALECTIN THERAPEUTICS INC (GALT) | United States | $0.399B | -11.06 |
| PROTHENA CORP PUBLIC LTD CO (PRTA) | Ireland | $0.428B | -11.53 |
| Turn Therapeutics Inc. (TTRX) | United States | $0.397B | -25.68 |
| CYPHERPUNK TECHNOLOGIES INC. (CYPH) | United States | $0.438B | -75.63 |
| Quoin Pharmaceuticals Ltd. (QNRX) | $0.443B | -17.85 |